NCT02688790 is a Phase 1 clinical trial of Dalbavancin in Bacterial Infections, sponsored by AbbVie.

Who is sponsoring NCT02688790?

NCT02688790 is sponsored by AbbVie.

What drugs are being tested in NCT02688790?

Interventions in NCT02688790: Dalbavancin.

What condition does NCT02688790 study?

NCT02688790 studies Bacterial Infections.

Is NCT02688790 still recruiting?

NCT02688790 is currently terminated. Last updated 29 March 2022.

Last reviewed 2022-03-29 · How we verify

NCT02688790

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

Terminated Phase 1 Last updated 29 March 2022

What this trial tests

Phase 1 trial testing Dalbavancin in Bacterial Infections in 8 participants. Terminated before completion.

Timeline

1 April 2016

Primary endpoint
3 April 2019

3 April 2019

Quick facts

Lead sponsor	AbbVie
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	8
Start date	1 April 2016
Primary completion	3 April 2019
Estimated completion	3 April 2019
Sites	5 locations across United States

Drugs / interventions tested

Dalbavancin (DALBAVANCIN) — full drug profile →

Conditions studied

Bacterial Infections — all drugs for Bacterial Infections →

Sponsor

AbbVie — full company profile →

Who can join

Under 28 Days, any sex, with Bacterial Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the Pharmacokinetic (PK) profile of a single intravenous (IV) infusion dose of dalbavancin, and to evaluate the safety and tolerability of a single dalbavancin IV infusion.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections.
Giorgobiani M, Burroughs MH, Antadze T, Carrothers TJ, et al · · 2023 · cited 17× · PMID 36476623 · DOI 10.1097/inf.0000000000003798
New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics.
Principi N, Argentiero A, Neglia C, Gramegna A, et al · · 2020 · cited 7× · PMID 33113966 · DOI 10.3390/ph13110333

Verify or expand the search:

Other trials of Dalbavancin

Trials testing the same drug.

NCT05046860 — Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements · NA · unknown
NCT04959799 — Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA) · completed
NCT04847921 — Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition · Phase 2, PHASE3 · terminated
NCT04775953 — DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia · Phase 2 · completed
NCT04624451 — Evaluation of Intravenous Dalbavancin for Peritonitis · terminated

Other recruiting trials for Bacterial Infections

Currently open trials in the same condition.

NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
NCT07104162 — A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal I · Phase 1 · recruiting
NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers · Phase 1 · recruiting
NCT07056881 — Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa · recruiting
NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women · Phase 2, PHASE3 · active not recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02688790 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 29 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02688790.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing